Showing results (671-680 of 709) with videos related to

Sort By:
Pageof 71
Oncology Letters|August 27, 2025
Radiomics-based prediction of HCC response to atezolizumab/bevacizumabIsaac Rodriguez, Abhinay Vellala, Timo Itzel, et al.
Journal of Hepatology|August 8, 2021
Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)Cornelius Engelmann, Adam Herber, Annegret Franke, et al.
The Lancet. Oncology|January 23, 2019
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialAndrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, et al.
The Lancet. Oncology|December 1, 2023
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trialJosep M Llovet, Masatoshi Kudo, Philippe Merle, et al.
The New England Journal of Medicine|July 25, 2008
Sorafenib in advanced hepatocellular carcinomaJosep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, et al.
Journal for Immunotherapy of Cancer|September 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinomaTim F Greten, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
The Journal of Clinical Investigation|January 26, 2005
The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivoAysefa Doganci, Tatjana Eigenbrod, Norbert Krug, et al.
Gut|June 10, 2024
PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinomaFriederike L Keggenhoff, Darko Castven, Diana Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2024
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaB Sangro, S L Chan, R K Kelley, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2025
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidenceGiulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
Pageof 71